Comparative assessment in healthy male volunteers under fasting conditions of the absorption and pharmacokinetics of 3 generic formulations of isotretinoin capsules against the innovator isotretinoin capsule in a pilot study
A single dose, randomized, blinded, 4 way crossover pilot pharmacokinetic study of 3 test formulations of isotretinoin capsules against the innovator isotretinoin capsule conducted under fasting conditions in healthy male volunteers
Zenith Technology Corp Ltd
16 participants
Oct 28, 2015
Interventional
Conditions
Summary
The objective of this study is to evaluate the pharmacokinetics of three test formulations of isotretinoin 40 mg capsule against the reference formulation (innovator brand of 40 mg isotretinoin capsule) following administration of a single oral dose in healthy male subjects under fasting conditions.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single dose, crossover study design whereby each participant receives the test formulations of isotretinoin, 1 x 40 mg capsule (T1, T2 and T3) on one occasion each and the innovator formulation of isotretinoin, 1 x 40 mg capsule on one occasion. The intervention for this trial is the test formulations of isotretinoin. No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with each dose). Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after each dose. Bathroom visits will be supervised to ensure no unauthorized water or food intake and for personal safety. Participants will be confined at the Clinical Site for 12 hours prior to dosing to ensure compliance and for 24 hours after dosing. Participants will be monitored for adverse events throughout the study. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 12 hours prior to dosing. Pre and post study laboratory tests will be completed to assess the health of the participants along with HIV, Hepatitis and drugs of abuse testing. Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure that the medication has been taken as directed. Each dose is separated by a one week washout period.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615001083583